GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Shiller PE Ratio

Clearside Biomedical (Clearside Biomedical) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Clearside Biomedical Shiller PE Ratio Historical Data

The historical data trend for Clearside Biomedical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Shiller PE Ratio Chart

Clearside Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clearside Biomedical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clearside Biomedical's Shiller PE Ratio

For the Biotechnology subindustry, Clearside Biomedical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Shiller PE Ratio falls into.



Clearside Biomedical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Clearside Biomedical's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Clearside Biomedical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.17/131.7762*131.7762
=-0.170

Current CPI (Mar. 2024) = 131.7762.

Clearside Biomedical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201409 0.000 100.428 0.000
201412 -0.217 99.070 -0.289
201503 -0.306 99.621 -0.405
201506 -0.427 100.684 -0.559
201509 -0.283 100.392 -0.371
201512 -0.421 99.792 -0.556
201603 -0.335 100.470 -0.439
201606 -0.620 101.688 -0.803
201609 -0.280 101.861 -0.362
201612 -0.450 101.863 -0.582
201703 -0.410 102.862 -0.525
201706 -0.540 103.349 -0.689
201709 -0.720 104.136 -0.911
201712 -0.650 104.011 -0.824
201803 -0.620 105.290 -0.776
201806 -0.650 106.317 -0.806
201809 -0.750 106.507 -0.928
201812 -0.680 105.998 -0.845
201903 -0.450 107.251 -0.553
201906 -0.150 108.070 -0.183
201909 -0.170 108.329 -0.207
201912 -0.070 108.420 -0.085
202003 -0.070 108.902 -0.085
202006 -0.130 108.767 -0.158
202009 -0.050 109.815 -0.060
202012 -0.140 109.897 -0.168
202103 -0.130 111.754 -0.153
202106 -0.110 114.631 -0.126
202109 -0.080 115.734 -0.091
202112 0.310 117.630 0.347
202203 -0.130 121.301 -0.141
202206 -0.130 125.017 -0.137
202209 -0.130 125.227 -0.137
202212 -0.160 125.222 -0.168
202303 -0.150 127.348 -0.155
202306 -0.150 128.729 -0.154
202309 -0.150 129.860 -0.152
202312 -0.080 129.419 -0.081
202403 -0.170 131.776 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Clearside Biomedical  (NAS:CLSD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Clearside Biomedical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical (Clearside Biomedical) Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Executives
Charles A. Deignan officer: Chief Financial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay director 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore 10 percent owner 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp director, 10 percent owner C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla officer: Chief Medical Officer C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Daniel H. White director, officer: President and CEO C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond officer: Chief Commercial Officer C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer director INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc 10 percent owner 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701

Clearside Biomedical (Clearside Biomedical) Headlines

From GuruFocus